Arena Turns In FDA Application

Luke Timmerman12/22/09

San Diego-based Arena Pharmaceuticals (NASDAQ: ARNA) said today it has filed its application to the FDA for clearance to start marketing lorcaserin for weight loss. The application includes information on 18 clinical trials that enrolled almost 8,600 patients, including the pivotal trials known as Bloom and Blossom. The company had forecasted previously it would complete the application by the end of 2009.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.